Announcements Trials

Browse Landscape Eligibility

Clinical Trials

1 trials

Recent Start date Enrollment

Disease Progression × Fulvestrant × 90 days × Clear all

Phase

Status

Sponsor Class

Study Type

Interventional 1

Sponsor

Cancer Type

Conditions

Breast Neoplasms 56 Neoplasm Metastasis 10 Ovarian Neoplasms 9 Endometrial Neoplasms 7 Neoplasms 6 Uterine Cervical Neoplasms 4 Prostatic Neoplasms 4 Triple Negative Breast Neoplasms 3 Squamous Cell Carcinoma of Head and Neck 3 Neoplasms by Site 3 Hereditary Sensory and Autonomic Neuropathies 3 Breast Diseases 3 Recurrence 2 Melanoma 2 Head and Neck Neoplasms 2 Colorectal Neoplasms 2 Carcinoma, Lobular 2 Breast Cancer Metastatic 2 Uterine Neoplasms 1 Urogenital Neoplasms 1 Urinary Bladder Neoplasms 1 Stomach Neoplasms 1 Small Cell Lung Carcinoma 1 Pancreatic Neoplasms 1 Malignant Neoplasms of Female Genital Organs 1 Lung Neoplasms 1 Locoregional Recurrence 1 Hormone Receptor Positive Breast Carcinoma 1 HR-positive, HER2-negative Breast Neoplasms 1 HR+/HER2- Breast Cancer 1

Interventions

capivasertib 2 niraparib 1 lutetium Lu 177 dotatate 1 fludarabine phosphate 1 fludarabine 1 copanlisib 1 axicabtagene ciloleucel 1 Receptors, Interleukin-6 1 Interleukin 1 Receptor Antagonist Protein 1 Fulvestrant 1 Cyclophosphamide 1

Date Range

30 days 90 days 1 year All

Options

Has results Has announcements

NCT06635447 2026-01-13

CAPItrue

AstraZeneca

Phase 3 Recruiting

Breast Neoplasms, Disease Progression

Data powered by HemOnc (CC BY 4.0) Colophon ⚡